The generation of purinome-targeted libraries as a means to diversify ATP-mimetic chemical classes for lead finding

Molecular Diversity

Volumn 16, Issue 1, 2012, Pages 27-51

  Felder, Eduard R ^a   Badari, Alessandra ^a   Disingrini, Teresa ^a   Mantegani, Sergio ^a   Orrenius, Christian ^a   Avanzi, Nilla ^a   Isacchi, Antonella ^a   Salom, Barbara ^a  

^a NERVIANO MEDICAL SCIENCES   (Italy)

Author keywords

ATPase inhibitors; Chemical space; Combinatorial chemistry; Compound collection; Drug design; Fragment based; Kinase inhibitors; Kinase selectivity; Solid phase synthesis

Indexed keywords

ABC TRANSPORTER; ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE MIMETIC AGENT; NMS P 743E; PEPTIDOMIMETIC AGENT; PHA P 456; PHA P 632; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; DRUG STRUCTURE; DRUG TARGETING; MOLECULAR LIBRARY; PRIORITY JOURNAL; PURINOME TARGETED LIBRARY;

ADENOSINE TRIPHOSPHATE; BINDING SITES; COMBINATORIAL CHEMISTRY TECHNIQUES; DATABASES AS TOPIC; DRUG DESIGN; HIGH-THROUGHPUT SCREENING ASSAYS; MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PYRAZOLES; REFERENCE STANDARDS; SMALL MOLECULE LIBRARIES;

EID: 84858701559     PISSN: 13811991     EISSN: 1573501X     Source Type: Journal    
DOI: 10.1007/s11030-012-9361-6     Document Type: Article

References (32)

1. Manning G, White DB, Martinez RTH, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298:1912-1934. doi:10.1126/science. 1075762 (Pubitemid 35425239)
2. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23:3-25. doi:10.1016/S0169-409X(96)00423-1
3. Leeson PD, Springthorpe B (2007) The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 6:881-890. doi:10.1038/nrd2445 (Pubitemid 350042396)
4. Accelrys (2009) Pipeline Pilot. 8.0 edn., San Diego, CA
5. Lobell M, Hendrix M, Hinzen B, Keldenich J, Meier H, Schmeck C, Schohe-Loop R, Wunberg T, Hillisch A (2006) In silico ADMET traffic lights as a tool for the prioritization of HTS hits. ChemMed-Chem 1:1229-1236. doi:10.1002/cmdc.200600168 (Pubitemid 44786929)
6. Lu JJ, Crimin K, Goodwin JT, Crivori P, Orrenius C, Xing L, Tandler PJ, Vidmar TJ, Amore BM, Wilson AGE, Stouten PFW, Burton PS (2004) Influence of molecular flexibility and polar surface area metrics on oral bioavailability in the rat. J Med Chem 47:6104-6107. doi:10.1021/jm0306529 (Pubitemid 39507351)
7. Veber DF, Johnson SR, Cheng H-Y, Smith BR, Ward KW, Kopple KD (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45:2615-2623. doi:10.1021/jm020017n (Pubitemid 34595232)
8. Tibco (2011) Spotfire. Somerville, MA
9. Malumbres M (2011) Physiological relevance of cell cycle kinases. Physiol Rev 91:973-1007. doi:10.1152/physrev.00025.2010
10. Zhang C, Kim S-H (2008) The Impact of protein kinase structures on drug discovery, Chapt 18. In: Stroud RM, Finer-Moore J (eds) Computational and structural approaches to drug discovery: ligand-protein interactions. The Royal Society of Chemistry, London, pp 349-365. doi:10.1039/9781847557964
11. Aronov AM, McClain B, Moody CS, Murcko MA (2008) Kinaselikeness and kinase-privileged fragments: toward virtual polypharmacology. J Med Chem 51:1214-1222. doi:10.1021/jm701021b (Pubitemid 351480383)
12. Posy SL, Hermsmeier MA, Vaccaro W, Ott K-H, Todderud G, Lippy JS, Trainor GL, Loughney DA, Johnson SR (2011) Trends in kinase selectivity: insights for target class-focused library screening. J Med Chem 54:54-66. doi:10.1021/jm101195a
13. Fancelli D, Moll J, Varasi M, Bravo R, Artico R, Berta D, Bindi S, Cameron A, Candiani I, Cappella P, Carpinelli P, Croci W, Forte B, Giorgini ML, Klapwijk J, Marsiglio A, Pesenti E, Rocchetti M, Roletto F, Severino D, Soncini C, Storici P, Tonani R, Zugnoni P, Vianello P (2006) 1,4,5,6- Tetrahydropyrrolo[3,4-c] pyrazoles: identification of a potent aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J Med Chem 49: 7247-7251 (Pubitemid 44886012)
14. Traquandi G, Ciomei M, Ballinari D, Casale E, Colombo N, Croci V, Fiorentini F, Isacchi A, Longo A, Mercurio C, Panzeri A, Pastori W, Pevarello P, Volpi D, Roussel P, Vulpetti A, Brasca MG (2010) Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors. J Med Chem 53:2171-2187. doi:10.1021/jm901710h
15. Menichincheri M (2009) First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. J Med Chem 52:293-307. doi:10.1021/jm800977q
16. Beria I, Bossi RT, Brasca MG, Caruso M, Ceccarelli W, Fachin G, Fasolini M, Forte B, Fiorentini F, Pesenti E, Pezzetta D, Posteri H, Scolaro A, Depaolini SR, Valsasina B (2011) NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Bioorg Med Chem Lett 21:2969-2974. doi:10.1016/j.bmcl.2011.03.054
17. Bossi RT, Saccardo MB, Ardini E, Menichincheri M, Rusconi L, Magnaghi P, Orsini P, Avanzi N, Borgia AL, Nesi M, Bandiera T, Fogliatto G, Bertrand JA (2010) Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors. Biochemistry 49:6813-6825. doi:10.1021/bi1005514
18. Colombo R, Caldarelli M, Mennecozzi M, Giorgini ML, Sola F, Cappella P, Perrera C, Re Depaolini S, Rusconi L, Cucchi U, Avanzi N, Bertrand JA, Bossi RT, Pesenti E, Galvani A, Isacchi A, Colotta F, Donati D, Moll JK (2010) Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase. Cancer Res 70:10255-10264. doi:10.1158/0008-5472.CAN-10-2101
19. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J (2000) Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 289:1938-1942. doi:10.1126/science.289.5486.1938
20. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 29:1046-1051. doi:10.1038/nbt.1990
21. Modugno M, Casale E, Soncini C, Rosettani P, Colombo R, Lupi R, Rusconi L, Fancelli D, Carpinelli P, Cameron AD, Isacchi A, Moll Jr (2007) Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. Cancer Res 67:7987-7990 (Pubitemid 47395130)
22. Chene P (2008) Challenges in design of biochemical assays for the identification of small molecules to target multiple conformations of protein kinases. Drug Discov Today 13:522-529. doi:10.1016/j.drudis.2008.03.023
23. Zuccotto F, Ardini E, Casale E, Angiolini M (2010) Through the "gatekeeper door": exploiting the active kinase conformation. J Med Chem 53:2681-2694. doi:10.1021/jm901443h
24. Chene P (2002) ATPases as drug targets: learning from their structure. Nat Rev Drug Discov 1:665-673. doi:10.1038/nrd894
25. Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW, Pearl LH (1999) Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 42:260-266. doi:10.1021/jm980403y (Pubitemid 29069861)
26. Dalvit C, Ardini E, Fogliatto GP, Mongelli N, Veronesi M (2004) Reliable high-throughput functional screening with 3-FABS. Drug Discov Today 9:595-602. doi:10.1016/S1359-6446(04)03161-7 (Pubitemid 38900509)
27. Dalvit C, Caronni D, Mongelli N, Veronesi M, Vulpetti A (2006) NMR-based quality control approach for the identification of false positives and false negatives in high throughput screening. Curr Drug Discov Technol 3:115-124. doi:10.2174/157016306778108875 (Pubitemid 44285197)
28. Massey A, Williamson D, Browne H, Murray J, Dokurno P, Shaw T, Macias A, Daniels Z, Geoffroy S, Dopson M, Lavan P, Matassova N, Francis G, Graham C, Parsons R, Wang Y, Padfield A, Comer M, Drysdale M, Wood M (2010) A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells. Cancer Chemother Pharmacol 66:535-545. doi:10.1007/s00280-009-1194-3
29. De Kloe GE, Bailey D, Leurs R, Esch IJP (2009) Transforming fragments into candidates: small becomes big in medicinal chemistry. Drug Discov Today 14:630-646. doi:10.1016/j.drudis.2009.03.009
30. de Jankowska J, Sobkowski M, StawiÅski J, Kraszewski A (1994) Studies on aryl H-phosphonates. I. An efficient method for the preparation of deoxyribo- and ribonucleoside 3′-H-phosphonate monoesters by transesterification of diphenyl H-phosphonate. Tetrahedron Lett 35:3355-3358. doi:10.1016/S0040-4039(00)76906-1
31. Zegzouti H, Zdanovskaia M, Hsiao K, Goueli SA (2009) ADPGlo: a bioluminescent and homogeneous ADP monitoring assay for kinases. Assay Drug Dev Technol 7:560-572. doi:10.1089/adt.2009.0222
32. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26:127-132. doi:10.1038/nbt1358